The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and value of GSK Plc's (NYSE:GSK) chronic obstructive pulmonary disease (COPD) ...
Credit: Getty Images. The FDA has expanded the approval of Breo Ellipta to include maintenance treatment of asthma in children 5 to 17 years of age. The Food and Drug Administration (FDA) has expanded ...
Dublin, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The "Global BREO Ellipta Drugs Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering. The global BREO ellipta drugs ...
DUBLIN--(BUSINESS WIRE)--The "Breo Ellipta" report has been added to ResearchAndMarkets.com's offering. Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol ...
Breo Ellipta (fluticasone furoate/vilanterol trifenatate) is a prescription drug used to treat chronic obstructive pulmonary disease (COPD) and asthma. Breo Ellipta’s cost may depend on factors such ...
The FDA granted approval to GlaxoSmithKline's ($GSK) new respiratory drug Breo Ellipta. By itself, that's a solid victory for GSK, which needs to build up its ...
The company is increasing its share of new-to-brand prescriptions with Breo, and that means that “as we go forward, all else equal, we should start to see our total prescription share start to move ...
GlaxoSmithKline expanded its COPD reach in Europe. The company announced Monday that the European Medicines Agency Committee for Medicinal Products for Human Use—familiarly known as EMA CHMP—approved ...
The prescribed dosage for Breo Ellipta may depend on your individual treatment plan. Factors like your condition, medical history, age, and other treatments you take may affect your dosage of Breo ...
We are initiating coverage on Innoviva with a long-term Buy rating and common stock price target of $16.89 to $24. Sales of Breo and Anoro Ellipta inhalers have picked up this year due to aggressive ...
SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for chronic obstructive pulmonary disease, the agency said Friday. The FDA announced the approval of Breo Ellipta ...
GlaxoSmithKline and Theravance’s Breo has been recommended for approval by an FDA advisory committee for asthma, but only in adults. Breo is already approved to treat chronic obstructive pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback